Targeting UBE4A has shown beneficial effects in some pathological conditions, such as inhibiting cancer cell proliferation by preventing UBE4A-mediated p53 degradation[23], and enhancing host antiviral responses by preventing UBE4A-mediated viperin degradation [24]. Here, RSAD2 is linked to cancer.